Life Molecular Imaging SA
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Life Molecular Imaging SA
On the heels of the FDA’s full approval of Biogen and Eisai’s Leqembi, AC Immune’s CEO is hopeful that a precision medicine approach with improved diagnosis, prevention and treatment of Alzheimer’s disease is not far down the road. With 16 clinical programs, notable partnerships and wholly owned assets, AC Immune holds a strong position to help reach that destination.
Mass screening of asymptomatic people is an expensive, daunting proposition, but very preliminary research with an amyloid beta blood test is spurring hope that a more practical way to identify those at risk will emerge in the future.
Tau-targeting Alzheimer's candidates, though historically rejected in favor of amyloid-beta targeting ones, have gained increasing interest from investors and larger pharma companies.
With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
- Diagnostic Imaging Equipment & Supplies
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.